# A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Study · id `cardio:ct-nct04521023` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04521023](<https://clinicaltrials.gov/study/NCT04521023>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04521023

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT04521023. Randomized; double masking; primary purpose treatment. Start 2017-09-20 (actual); primary completion 2020-01-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT04521023, source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)
- Started: 2017-09-20 (actual) (ClinicalTrials.gov record NCT04521023, source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)
- Primary completion: 2020-01-28 (actual) (ClinicalTrials.gov record NCT04521023, source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)
- Completion: 2020-06-03 (actual) (ClinicalTrials.gov record NCT04521023, source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04521023, source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04521023-2020-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
- Condition: Hypertension
- Intervention (Drug): Cantabell Tab
- Intervention (Drug): Candemore Plus Tab
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: c8e5e852bb1ce616392b190fc8a7c7a89974d3dec4dfbf8d5a71891600a20562
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
